Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis

Patients with malignant melanoma have a 5-year survival rate of only 15–20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for the majority of patients with melanoma harboring BRAF(V600E) mutation, over 90% of patients relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanneste, Marion, Feddersen, Charlotte R., Varzavand, Afshin, Zhu, Elliot Y., Foley, Tyler, Zhao, Lei, Holt, Kathleen H., Milhem, Mohammed, Piper, Robert, Stipp, Christopher S., Dupuy, Adam J., Henry, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169429/
https://www.ncbi.nlm.nih.gov/pubmed/32346533
http://dx.doi.org/10.3389/fonc.2020.00442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169429/
https://www.ncbi.nlm.nih.gov/pubmed/32346533
http://dx.doi.org/10.3389/fonc.2020.00442

Ejemplares similares